AstraZeneca’s Imfinzi plus Imjudo recommended for approval in the EU

The Anglo-Swedish pharma giant said the Committee for Medicinal Products for Human Use of the European Medicines Agency based its opinion on results from the Himalaya Phase 3 trial, and results from the Poseidon Phase 3 trial.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.